ReviewDrugs in context2020
Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.
Review in Drugs in context, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis.Scientific reports · 2022Pooled it
- Exonic Variation in HLA-C, CFB, and TAP2 Associated With Increased Risk for Comorbid Crohn's Disease and Psoriasis.International journal of dermatology · 2026Article
- The overlooked surface: cutaneous manifestations of inflammatory bowel disease.Translational gastroenterology and hepatology · 2026Review
- The gut-bone axis in ankylosing spondylitis: mechanistic insights and the translational gap.Clinical and experimental medicine · 2025Review
- Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study.BMJ open gastroenterology · 2025Article
- Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease.European journal of medical research · 2025Article
- Targeting Interferon-Gamma (IFN-γ)-Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances.Mediators of inflammation · 2025Review
- A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab.Frontiers in pharmacology · 2025Article
- Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection.Cureus · 2024Review
- Putting Data into Practice: A Review of Phase III and Long-Term Efficacy Data for Bimekizumab for Plaque Psoriasis.The Journal of clinical and aesthetic dermatology · 2024Review
- Colitis induced by IL-17A-inhibitors.Clinical journal of gastroenterology · 2024Article
- A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis.Biomedicines · 2023Review
- The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors.Biomedicines · 2023Review
- Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.Dermatology and therapy · 2023Review
- Editorial: Exploration of genetic variation, drug response, and interactions between gastrointestinal disorders and other diseases.Frontiers in pharmacology · 2023Article
- IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis.Frontiers in pharmacology · 2023Article
- The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases.Current issues in molecular biology · 2022Review
- Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.Rheumatology and therapy · 2022Review
- New onset severe ulcerative colitis following Ixekizumab therapy.Archive of clinical cases · 2022Article
- Inflammatory bowel disease induced by bimekizumab.Przeglad gastroenterologiczny · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin 17 (IL-17) inhibitors provide an excellent treatment option for patients with psoriasis and psoriatic arthritis, resulting in high levels of efficacy for skin clearance and joint improvement. Safety has also been established in clinical trials for this group of biologic agents; however, rare case reports of exacerbation or induction of inflammatory bowel disease (IBD) have been reported in the literature. No causal relationship has been established. When IL-17 inhibitors were investigated for the management of IBD, no benefit was found and worsening of disease was noted for some patients. IBD is more common in patients with psoriasis and, therefore, it remains unknown if these drugs cause de novo IBD or if the reported cases of IBD in patients on IL-17 therapy is due to the background risk in this predisposed population who may have already had an underlying or subclinical disease. METHODS/
resultsA literature search was conducted for the terms 'IL-17 inhibitor,' 'ixekizumab,' 'secukinumab,' 'brodalumab' and 'inflammatory bowel disease,' 'ulcerative colitis,' and 'Crohn's disease' in PubMed and Google Scholar. Cases of new-onset or exacerbation of IBD were identified in the literature along with postmarketing pharmacovigilance data. These cases will be reviewed in this paper.
conclusionsIL-17 inhibitors have proven efficacy for the treatment of psoriasis and psoriatic arthritis with a strong safety profile. However, rare cases of IBD onset and exacerbation in patients on IL-17 inhibitors have been reported in the literature, highlighting the need to select patients and therapeutic choices appropriately when treating this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.